

Tara Friebe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4180067/publications.pdf>

Version: 2024-02-01

28
papers

6,237
citations

257357

24
h-index

501076

28
g-index

28
all docs

28
docs citations

28
times ranked

7083
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Risk-Reducing Surgery in <i>BRCA1</i> or <i>BRCA2</i> Mutation Carriers With Cancer Risk and Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 967.	3.8	1,241
2	Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: The PROSE Study Group. <i>Journal of Clinical Oncology</i> , 2004, 22, 1055-1062.	0.8	1,095
3	Risk-Reducing Salpingo-Oophorectomy for the Prevention of <i>BRCA1</i> - and <i>BRCA2</i> -Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 1331-1337.	0.8	522
4	Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: The PROSE Study Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 7804-7810.	0.8	396
5	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1347.	3.8	390
6	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	9.4	356
7	Mortality after bilateral salpingo-oophorectomy in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: a prospective cohort study. <i>Lancet Oncology</i> , The, 2006, 7, 223-229.	5.1	333
8	Characterization of <i>BRCA1</i> and <i>BRCA2</i> Mutations in a Large United States Sample. <i>Journal of Clinical Oncology</i> , 2006, 24, 863-871.	0.8	298
9	Genome-Wide Association Study in <i>BRCA1</i> Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003212.	1.5	244
10	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	1.1	224
11	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With <i>BRCA</i> Mutations. <i>JAMA Oncology</i> , 2016, 2, 1434.	3.4	189
12	Modifiers of Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: A Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju091.	3.0	176
13	<i>CYP3A4</i> , <i>CYP3A5</i> , and <i>CYP3A43</i> Genotypes and Haplotypes in the Etiology and Severity of Prostate Cancer. <i>Cancer Research</i> , 2004, 64, 8461-8467.	0.4	115
14	Validity of Models for Predicting <i>BRCA1</i> and <i>BRCA2</i> Mutations. <i>Annals of Internal Medicine</i> , 2007, 147, 441.	2.0	106
15	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016, 7, 11375.	5.8	93
16	Bilateral Prophylactic Oophorectomy and Bilateral Prophylactic Mastectomy in a Prospective Cohort of Unaffected <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Clinical Breast Cancer</i> , 2007, 7, 875-882.	1.1	77
17	Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of <i>BRCA1/2</i> mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 195-203.	1.1	58
18	Use of risk-reducing surgeries in a prospective cohort of 1,499 <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 397-406.	1.1	56

#	ARTICLE	IF	CITATIONS
19	Modification of <i>BRCA1</i> -Associated Breast and Ovarian Cancer Risk by <i>BRCA1</i> -Interacting Genes. <i>Cancer Research</i> , 2011, 71, 5792-5805.	0.4	49
20	Inheritance of deleterious mutations at both <i>BRCA1</i> and <i>BRCA2</i> in an international sample of 32,295 women. <i>Breast Cancer Research</i> , 2016, 18, 112.	2.2	42
21	The spectrum of <i>BRCA1</i> and <i>BRCA2</i> pathogenic sequence variants in Middle Eastern, North African, and South European countries. <i>Human Mutation</i> , 2019, 40, e1-e23.	1.1	34
22	Modification of Ovarian Cancer Risk by <i>BRCA1/2</i> -Interacting Genes in a Multicenter Cohort of <i>BRCA1/2</i> Mutation Carriers. <i>Cancer Research</i> , 2009, 69, 5801-5810.	0.4	31
23	Breast and Ovarian Cancer Risk and Risk Reduction in Jewish <i>BRCA1/2</i> Mutation Carriers. <i>Journal of Clinical Oncology</i> , 2012, 30, 1321-1328.	0.8	31
24	<i>BRCA1</i> and <i>BRCA2</i> pathogenic sequence variants in women of African origin or ancestry. <i>Human Mutation</i> , 2019, 40, 1781-1796.	1.1	26
25	No clinical utility of <i>KRAS</i> variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	0.6	18
26	Active recruitment increased enrollment in a hereditary cancer registry. <i>Journal of Clinical Epidemiology</i> , 2004, 57, 1172-1176.	2.4	16
27	Risk factors for breast cancer subtypes among Black women undergoing screening mammography. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 827-835.	1.1	12
28	Clinical and sociodemographic factors associated with late stage cervical cancer diagnosis in Botswana. <i>BMC Women's Health</i> , 2021, 21, 267.	0.8	9